Episode 46: Servier

Send a text

In this episode of Petri Dish Perspectives, we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the physician-pharmacist Jacques Servier, the company grew from a tiny laboratory in Orléans into a global powerhouse in cardiovascular and metabolic medicine. For decades, Servier built its reputation developing treatments for hypertension and diabetes while operating outside the pressures of the public stock market.

But the fortress eventually cracked.

The company became embroiled in one of the most devastating medical scandals in European history surrounding the drug Mediator (benfluorex). After being marketed for decades as a diabetes treatment, the drug was linked to severe heart valve damage and pulmonary hypertension, triggering a national crisis in France and a landmark trial that reshaped pharmaceutical oversight.

Yet Servier’s story does not end with scandal.

In the past decade, the company has undergone a dramatic transformation, pivoting billions of euros into oncology research and acquiring cutting-edge therapies targeting rare cancers. From precision leukemia drugs like Tibsovo to the breakthrough brain-tumor therapy Voranigo, Servier is rebuilding itself as a major force in targeted cancer medicine.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#Biotech #RareDisease #BioMarin #DrugDevelopment #GeneticDiseases #Pharma #Biotechnology #LifeSciences #HealthcareInnovation #GeneTherapy #BiotechPodcast #PetriDishPerspectives

Support the show

© 2026 Petri Dish Perspectives LLC. All rights reserved.